Red Blood Cell Transfusion and Mortality in Trauma Patients: Risk-Stratified Analysis of an Observational Study
Background:
Haemorrhage is a common cause of death in trauma patients. Although transfusions are extensively used in the care of bleeding trauma patients, there is uncertainty about the balance of risks and benefits and how this balance depends on the baseline risk of death. Our objective was to evaluate the association of red blood cell (RBC) transfusion with mortality according to the predicted risk of death.
Methods and Findings:
A secondary analysis of the CRASH-2 trial (which originally evaluated the effect of tranexamic acid on mortality in trauma patients) was conducted. The trial included 20,127 trauma patients with significant bleeding from 274 hospitals in 40 countries. We evaluated the association of RBC transfusion with mortality in four strata of predicted risk of death: <6%, 6%–20%, 21%–50%, and >50%. For this analysis the exposure considered was RBC transfusion, and the main outcome was death from all causes at 28 days. A total of 10,227 patients (50.8%) received at least one transfusion. We found strong evidence that the association of transfusion with all-cause mortality varied according to the predicted risk of death (p-value for interaction <0.0001). Transfusion was associated with an increase in all-cause mortality among patients with <6% and 6%–20% predicted risk of death (odds ratio [OR] 5.40, 95% CI 4.08–7.13, p<0.0001, and OR 2.31, 95% CI 1.96–2.73, p<0.0001, respectively), but with a decrease in all-cause mortality in patients with >50% predicted risk of death (OR 0.59, 95% CI 0.47–0.74, p<0.0001). Transfusion was associated with an increase in fatal and non-fatal vascular events (OR 2.58, 95% CI 2.05–3.24, p<0.0001). The risk associated with RBC transfusion was significantly increased for all the predicted risk of death categories, but the relative increase was higher for those with the lowest (<6%) predicted risk of death (p-value for interaction <0.0001). As this was an observational study, the results could have been affected by different types of confounding. In addition, we could not consider haemoglobin in our analysis. In sensitivity analyses, excluding patients who died early; conducting propensity score analysis adjusting by use of platelets, fresh frozen plasma, and cryoprecipitate; and adjusting for country produced results that were similar.
Conclusions:
The association of transfusion with all-cause mortality appears to vary according to the predicted risk of death. Transfusion may reduce mortality in patients at high risk of death but increase mortality in those at low risk. The effect of transfusion in low-risk patients should be further tested in a randomised trial.
Trial registration:
www.ClinicalTrials.gov NCT01746953
Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Red Blood Cell Transfusion and Mortality in Trauma Patients: Risk-Stratified Analysis of an Observational Study. PLoS Med 11(6): e32767. doi:10.1371/journal.pmed.1001664
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001664
Souhrn
Background:
Haemorrhage is a common cause of death in trauma patients. Although transfusions are extensively used in the care of bleeding trauma patients, there is uncertainty about the balance of risks and benefits and how this balance depends on the baseline risk of death. Our objective was to evaluate the association of red blood cell (RBC) transfusion with mortality according to the predicted risk of death.
Methods and Findings:
A secondary analysis of the CRASH-2 trial (which originally evaluated the effect of tranexamic acid on mortality in trauma patients) was conducted. The trial included 20,127 trauma patients with significant bleeding from 274 hospitals in 40 countries. We evaluated the association of RBC transfusion with mortality in four strata of predicted risk of death: <6%, 6%–20%, 21%–50%, and >50%. For this analysis the exposure considered was RBC transfusion, and the main outcome was death from all causes at 28 days. A total of 10,227 patients (50.8%) received at least one transfusion. We found strong evidence that the association of transfusion with all-cause mortality varied according to the predicted risk of death (p-value for interaction <0.0001). Transfusion was associated with an increase in all-cause mortality among patients with <6% and 6%–20% predicted risk of death (odds ratio [OR] 5.40, 95% CI 4.08–7.13, p<0.0001, and OR 2.31, 95% CI 1.96–2.73, p<0.0001, respectively), but with a decrease in all-cause mortality in patients with >50% predicted risk of death (OR 0.59, 95% CI 0.47–0.74, p<0.0001). Transfusion was associated with an increase in fatal and non-fatal vascular events (OR 2.58, 95% CI 2.05–3.24, p<0.0001). The risk associated with RBC transfusion was significantly increased for all the predicted risk of death categories, but the relative increase was higher for those with the lowest (<6%) predicted risk of death (p-value for interaction <0.0001). As this was an observational study, the results could have been affected by different types of confounding. In addition, we could not consider haemoglobin in our analysis. In sensitivity analyses, excluding patients who died early; conducting propensity score analysis adjusting by use of platelets, fresh frozen plasma, and cryoprecipitate; and adjusting for country produced results that were similar.
Conclusions:
The association of transfusion with all-cause mortality appears to vary according to the predicted risk of death. Transfusion may reduce mortality in patients at high risk of death but increase mortality in those at low risk. The effect of transfusion in low-risk patients should be further tested in a randomised trial.
Trial registration:
www.ClinicalTrials.gov NCT01746953
Please see later in the article for the Editors' Summary
Zdroje
1. SauaiaA, MooreFA, MooreEE, MoserKS, BrennanR, et al. (1995) Epidemiology of trauma deaths: a reassessment. J Trauma 38: 185–193.
2. KauvarDS, LeferingR, WadeCE (2006) Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma 60 (Suppl 6)S3–S11.
3. RossaintR, BouillonB, CernyV, CoatsTJ, DuranteauJ, et al. (2010) Management of bleeding following major trauma: an updated European guideline. Crit Care 14: R52.
4. WilkinsonKL, BrunskillSJ, DoreeC, HopewellS, StanworthS, et al. (2011) The clinical effects of red blood cell transfusions: an overview of the randomised controlled trials evidence base. Transfus Med Rev 25: 145–155.
5. World Health Organization (2011) Global Database on Blood Safety: summary report 2011. Available: http://www.who.int/bloodsafety/global_database/GDBS_Summary_Report_2011.pdf. Accessed 12 May 2014.
6. MarikPR, CorwinHL (2008) Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 36: 2667–2674.
7. CarsonJL, CarlessPA, HebertPC (2012) Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Review 2012: CD002042.
8. TienH, NascimentoB, CallumJ, RizoliS (2007) An approach to transfusion and hemorrhage in trauma: current perspectives on restrictive transfusion strategies. Can J Surg 50: 202–209.
9. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, et al (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376: 23–32.
10. PerelP, Prieto-MerinoD, ShakurH, ClaytonT, LeckyF, et al. (2012) Predicting early death in patients with traumatic bleeding: development and validation of a prognostic model. BMJ 345: e5166 doi:10.1136/bmj.e5166
11. RaoSV, JollisJG, HarringtonRA, GrangerCB, NewbyLK, et al. (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292: 1555–1562.
12. SilvainJ, PenaA, CaylaG, BriegerD, Bellemain-AppaixA, et al. (2010) Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. Eur Heart J 31: 2816–2821 doi:10.1093/eurheartj/ehq209
13. MacMahonAD (2003) Approaches to combat confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 12: 551–558.
14. SnyderCW, WeinbergJA, McGwinGJr, MeltonSM, GeorgeRL, et al. (2009) The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma 66: 358–362.
15. SturmerT, RothmanKJ, AvornJ, GlynnRJ (2010) Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol 172: 843–854.
16. NapolitanoLM, KurekS, LuchetteFA, AndersonGL, BardMR, et al. (2009) Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. J Trauma 67: 1439–1442.
17. CarsonJL, GrossmanBJ, KleinmanS, TinmouthAT, MarquesMB, et al. (2012) Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 157: 49–58.
18. RobertsI, PerelP, Prieto-MerinoD, ShakurH, CoatsT, et al. (2012) Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ 345: e5839.
19. FullerG, BouamraO, WoodfordM, JenksT, StanworthS, et al. (2012) Recent massive transfusion practice in England and Wales: view from a trauma registry. Emerg Med J 29: 118–123.
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2014 Číslo 6
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Pleiotropní účinky statinů na kardiovaskulární systém
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- Zástava srdce u pacienta se střelnými ranami – kazuistika
- Statinová intolerance
Najčítanejšie v tomto čísle
- Melanocytic Nevi as Biomarkers of Breast Cancer Risk
- Antiretroviral Therapy for Refugees and Internally Displaced Persons: A Call for Equity
- Efficacy of Pneumococcal Nontypable Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial
- Blood Transfusions following Trauma: Finding an Evidence-Based Vein